Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $5.64 Million - $7.36 Million
-142,300 Reduced 32.65%
293,500 $15.2 Million
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $4.88 Million - $6.43 Million
121,300 Added 38.57%
435,800 $18.1 Million
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $3.67 Million - $4.16 Million
-76,500 Reduced 19.57%
314,500 $17.1 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $12.1 Million - $14.4 Million
249,000 Added 175.35%
391,000 $20.1 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $7.28 Million - $8.14 Million
-125,800 Reduced 46.98%
142,000 $8.24 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $11.6 Million - $12.9 Million
182,300 Added 213.22%
267,800 $17.1 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $3.53 Million - $4 Million
53,700 Added 168.87%
85,500 $5.93 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $588,928 - $697,374
-8,600 Reduced 21.29%
31,800 $2.29 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $5,252 - $3.1 Million
40,400 New
40,400 $2.87 Million
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $1.57 Million - $2.29 Million
-33,900 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $6.53 Million - $8.51 Million
-132,600 Reduced 79.64%
33,900 $2.18 Million
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $2.44 Million - $2.89 Million
57,000 Added 52.05%
166,500 $8.44 Million
Q2 2019

Aug 14, 2019

BUY
$44.62 - $49.34 $4.74 Million - $5.24 Million
106,300 Added 3321.88%
109,500 $4.97 Million
Q1 2019

May 15, 2019

BUY
$45.12 - $53.8 $144,384 - $172,160
3,200 New
3,200 $153,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.